Priveterra Acquisition Corp. (NASDAQ:PMGM) announced this afternoon that its special meeting, intended to approve its combination with AEON Biopharma, has been adjourned for the seventh consecutive time.
Given the SPAC’s completion deadline of August 11, it is unlikely that this will be the last adjournment we will see for this completion vote.
Initially scheduled for noon today, the meeting has now been pushed back until June 30 at 4:00 p.m. Priveterra continues to reiterate its commitment to utilizing the extended time during the postponement to further engage with its shareholders.
The deal with AEON Biopharma includes a $40 million minimum cash condition, half of which has already been secured through a $20 million commitment from existing AEON investors at $7 per share. But, Priveterra’s trust, originally totaling $276 million, has been reduced to about $20.3 million after seeing 92.7% of shares redeemed in earlier votes.
Priveterra inked its $201.8 million business combination with drug developer AEON on December 13. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
Lakeshore Acquisition III Corp. (NASDAQ:LCCCU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “LCCCU”, Wednesday, April 30, 2025. The new SPAC aims to conduct a broad search for a target with a team that has previously closed business combinations in the...
Churchill Capital Corp X (NASDAQ:CCCXU) has filed for a $300 million SPAC with a broad search focus, to add to the portfolio of Churchill deals. Five Churchill deals have closed (I, II, III, IV, and AltC), while V, VI and VII liquidated in the SPAC downturn. However, keep in mind that the Churchill team still...
Black Hawk Acquisition Corp (NASDAQ:BKHA) has entered into a definitive agreement to combine with biotech firm Vesicor Therapeutics at a pre-money equity value of $70 million. San Gabriel, California-based Vesicor is developing treatments utilizing extracellular vesicles as both a therapy themselves and as a delivery system for other medicines. The combined company is expected to...
At the SPAC of Dawn SPAC activity has continued to heat up as the market now has a new business combination to digest alongside two new SPACs making their debut on the Nasdaq later today. Three more new SPACs have filed their initial S-1s to eventually join them. That makes 29 SPAC IPOs and 49...
Digital Asset Acquisition Corp. (NASDAQ:DAAQU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DAAQU”, Tuesday, April 29, 2025. The new SPAC aims to combine with a target company in the digital asset and cryptocurrency sectors. Digital Asset Acquisition Corp.’s management team...